Padua, Italy - Although juvenile localized scleroderma is typically thought of as a skin disease, Dr Francesco Zulian reports in the September 2005 issue of Arthritis & Rheumatism that 22.4% of ...

There are 2 main types of scleroderma: localized and systemic. The localized type only affects the skin, whereas the systemic type affects the skin and other body parts.

Patients with 3 subtypes of juvenile localized scleroderma (linear, generalized, and mixed) in the active phase were referred to a single center in Italy. They were randomly assigned in a 2:1 ...

Localized Scleroderma usually affects the skin and rarely spreads elsewhere, while Systematic Scleroderma can affect other organs of the body besides the skin. What are symptoms of Scleroderma?

Localized scleroderma patients usually live normal lifespans. Yet about half of systemic patients, especially with widespread skin involvement and internal organ fibrosis, will see their lives cut ...

There are two types of scleroderma. Localized scleroderma is confined to the skin on the hand and face while in systemic scleroderma the disease could spread to the internal organs.

Scleroderma is an autoimmune disorder. It's estimated 300,000 Americans suffer from the disease with about one-third of those having the systemic form. Localized scleroderma patients usually live ...

Generally, localized scleroderma is relatively mild and doesn’t affect internal organs, according to the Scleroderma Foundation.

Localized scleroderma is relatively mild, and is usually found on a few places of the skin or muscles. The internal organs are not usually affected and people affected with localized scleroderma ...

Localized scleroderma can take the form of reddish patches of skin that thicken into firm, oval-shaped areas. The center of each patch becomes ivory colored with violet borders.

However, the National Scleroderma Foundation states that an estimated 300,000 Americans have the disease. There are two major forms of Scleroderma: localized scleroderma and systemic scleroderma.

Fibrocell Science announced that the Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013 for the treatment of moderate to severe localized scleroderma.